![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-desktop-w27gif-57924.gif)
![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-mobile-w27gif-62411.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The collaboration aims to accelerate the development of new and more stable enzymes. Creating improved engineering processes for designer enzymes could lead to safer and more effective therapeutics, such as enzyme replacement therapy, for a broad range of genetic diseases.
Lead Product(s): Undisclosed
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Large molecule
Partner/Sponsor/Collaborator: University of Edinburgh
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration December 14, 2023
Details:
The collaboration combines Neochromosome’s neoYeastTM platform with Sumitovant’s DrugOMETM computational ecosystem to identify novel proteins that would benefit from non-canonical amino acid chemistries that are not found in nature.
Lead Product(s): Undisclosed
Therapeutic Area: Technology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Partner/Sponsor/Collaborator: Sumitovant Biopharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 19, 2023